Literature DB >> 2623976

Uricosuric effect of irtemazole in hyperuricemic patients without and with renal insufficiency.

I Kamilli1, U Gresser, T Pellkofer, W Löffler, N Zöllner.   

Abstract

A single oral dose of 50 mg irtemazole exhibited a clear cut uricosuric effect in five patients with hyperuricemia and normal renal function. The average maximal decrease of plasma uric acid was 46.1% compared to the initial value; it was reached between 6 h and 12 h after drug administration. Extent and course of plasma uric acid showed no differences between normouricemic (5) and hyperuricemic subjects. In four patients suffering from hyperuricemia and renal insufficiency only a minor effect of irtemazole was seen. The average maximal decrease of plasma uric acid reached 12.8% compared to the initial value. It occurred between 8 h and 12 h after drug ingestion. In both normouricemic and hyperuricemic subjects irtemazole acts more quickly than benzbromarone and probenecid. The duration of its uricosuric effect is shorter. Like benzbromarone, irtemazole exhibits only a minor effect in patients with reduced creatinine clearance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2623976

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  2 in total

1.  Rapid onset of uricosuria after oral administration of irtemazole, an uricosuric substance.

Authors:  U Gresser; U Kronawitter; O Adjan; N Zöllner
Journal:  Klin Wochenschr       Date:  1989-10-17

Review 2.  Pharmacokinetic-pharmacodynamic relationships in phase I/phase II of drug development.

Authors:  A Van Peer; E Snoeck; M L Huang; J Heykants
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.